Hepatitis C

Hepatitis C is a blood-borne virus that infects the liver, where it causes significant inflammation, damage and disruption of normal liver function. According to estimates by the World Health Organization, around 3 to 4 million people worldwide are infected with hepatitis C every year.

What is Hepatitis C?

Hepatitis C infection is a liver infection caused by the Hepatitis C virus. Infection with hepatitis C may damage the liver leading to chronic infection.

Hepatitis C Acute Infection

Chronic Hepatitis C Infection

Hepatitis C Prevention

What is the Hepatitis C Virus?

Early and Late Symptoms of Hepatitis C

Tests for Hepatitis C

Hepatitis C Diagnosis

Hepatitis C Transmission

Hepatitis C Epidemiology

HCV and Rheumatic Disease

How is Hepatitis C Transmitted?

See more featured articles »

Hepatitis C Treatment

Hepatitis C treatment: no benefits and possible harm

Is Hepatitis Preventable?

Hepatitis C History

Latest Hepatitis C News and Research

New integrated framework advances precision surgery for liver cancer

Hepatocellular carcinoma is the sixth most common malignancy and the third leading cause of cancer-related death globally.

9 Sep 2026

Could scorpion venom inspire new treatments for liver disease?

Scorpion venom peptides show promising anti-inflammatory, antiviral, analgesic, and immunomodulatory effects, with experimental evidence suggesting that some candidates could target pathways involved in chronic liver disease and viral hepatitis. The review highlights Kv1.3-blocking peptides and antiviral compounds as potential therapeutic leads, while emphasizing that limited hepatic efficacy data, poor pharmacokinetics, immunogenicity, and manufacturing challenges must be overcome before clinical translation.

8 Sep 2026

Nanoparticle flu vaccine design could pave way for broader protection

Influenza viruses constantly shapeshift to evade recognition by the immune system. This shapeshifting occurs in critical proteins like hemagglutinin (HA), which controls how the virus attaches to human cells before entering them.

2 Sep 2026

Blocking a key protein protects against metabolic liver damage

Obesity-related metabolic liver disease affects hundreds of millions of people worldwide, but only some fraction of those livers develop scarring, become inflamed, and eventually fail. University of Utah researchers have identified a protein, EFHD1, that appears to drive that transition by triggering an out-of-place antiviral immune response.

1 Sep 2026

Lancet review examines possible amyloid-beta transmission through blood transfusions

A review and opinion piece published in The Lancet and led by UCL (University College London) and UCLH researchers discusses the possibility that blood transfusions may inadvertently transmit harmful brain proteins, and whether additional safety measures are warranted as a precaution whilst further research is conducted to better understand these potential risks.

21 Aug 2026

Novel norovirus vaccine approach may be adaptable for other RNA viruses

Every RNA virus — from stomach bugs and influenza to chickenpox and the common cold — has its own story to tell, with a unique combination of symptoms, rates of transmission, duration, and chemical blueprint.

19 Aug 2026

'Me-too' drugs drive increased spending through higher prescribing

A long-running debate over prescription drug costs has centered on whether drug manufacturers are better rewarded for truly innovative medicines or so-called "me-too" drugs that may offer only incremental improvements over existing treatments but still command high prices.

3 Aug 2026

Newly-discovered protein acts as off switch for human immune cells

Mayo Clinic researchers have identified a protein that cancer cells use to shut down the body's immune response, a discovery that could help scientists develop new treatments that make cancer immunotherapies more effective.

3 Aug 2026

Integration is key to fighting global epidemics, WHO reports

The World Health Organization (WHO) today launched a new report assessing progress in implementing the Global Health Sector Strategies (GHSS) on HIV, viral hepatitis and sexually transmitted infections (STIs) for 2022–2030.

28 Jul 2026

Europe risks missing target to eliminate viral hepatitis by 2030

While Europe has made steady progress in preventing hepatitis B and C, with the prevalence of hepatitis B now at near-zero levels among children below five years old, an uneven implementation of key measures means that the region is set to miss the 2030 target to eliminate viral hepatitis as a public health threat, according to new data from the European Centre for Disease Prevention and Control (ECDC) on World Hepatitis Day.

28 Jul 2026

Strategic healthcare interventions bring Japan close to eliminating hepatitis

Hepatitis B (HBV) and hepatitis C (HCV) are viral infections that can lead to health conditions such as cirrhosis, cancer, and potentially death if unmanaged. HBV can be transmitted through sexual contact, blood exposure, and mother-to-child transmission, while HCV is primarily transmitted through blood-to-blood contact.

25 Jun 2026

NIH funding supports development of AI tools to prevent HIV, hepatitis C and overdose

Natasha Martin, DPhil, professor and vice chief of Global Public Health in the Division of Infectious Diseases and Global Public Health at UC San Diego School of Medicine, has been awarded a five-year, $5.6 million Avant-Garde Award from the National Institute on Drug Abuse (NIDA), one of the most prestigious and competitive NIH research awards.

23 Jun 2026

Study finds critical gaps in prenatal syphilis screening in Ontario

Congenital syphilis is entirely preventable-yet new research shows critical gaps in prenatal screening that are leaving some infants at risk.

19 May 2026

Study reveals persistent gaps in Ontario’s prenatal syphilis screening coverage

According to new research in CMAJ, 1 in 5 pregnant people in Ontario did not receive timely syphilis screening, which is critical for preventing syphilis infection in newborns (Canadian Medical Association Journal).

19 May 2026

DNA-guided CRISPR system targets RNA and expands Cas12 beyond gene editing

Researchers developed ΨDNA, a DNA-based CRISPR guide that allows Cas12 enzymes to target RNA with high specificity while retaining compatibility with DNA-editing workflows. The platform detected HCV RNA in clinical samples and enabled programmable RNA knockdown, multiplex targeting, and RNA modification in human cells.

18 May 2026

New CRISPR breakthrough promises more affordable disease diagnostics

A team of engineers at the University of Florida has developed a new form of CRISPR technology that could make diagnostics and treatments safer, more precise, and more affordable, while opening the door to entirely new ways of controlling disease.

15 May 2026

New imaging technique maps 38000 liver cells to solve fibrosis

The liver is often called a "silent organ," as it can sustain significant damage without obvious symptoms. But when injury is prolonged, whether from alcohol, poor diet, or chronic hepatitis virus infection, it triggers fibrosis: a progressive hardening and scarring of liver tissue.

14 May 2026

Colbopasvir plus sofosbuvir achieves high cure rates in chronic hepatitis C

In this real‑world multicenter study (Wenzhou, China), 113 chronic hepatitis C patients received colbopasvir (60 mg) + sofosbuvir (400 mg) daily for 12 weeks. Overall SVR12 was 99.1% (112/113). SVR12 was 100% for genotypes 3a, 3b, 6a, and compensated cirrhosis, 93.3% for genotype 1b, and 90% for HBV co‑infection.

14 May 2026

Hepatitis C infection associated with reduced portal insulin levels

Insulin resistance is a common extrahepatic manifestation of hepatitis C virus (HCV) infection (HCVi), but its mechanism is poorly understood.

28 Apr 2026

WHO report shows measurable progress in reducing global hepatitis infections

Global efforts to combat viral hepatitis are delivering measurable progress in reducing infections and deaths, but the disease remains a major global health challenge, according to a new World Health Organization (WHO) report released today at the World Hepatitis Summit.

28 Apr 2026